{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:14:07Z","timestamp":1767705247819,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013394","name":"REGENXBIO Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ymgmr.2023.100956","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T22:33:05Z","timestamp":1674167585000},"page":"100956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome"],"prefix":"10.1016","volume":"34","author":[{"given":"Kanut","family":"Laoharawee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"Podetz-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajya M.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalitha R.","family":"Belur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter C.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen F.","family":"Kozarsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Scott","family":"McIvor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"The Mucopolysaccharidoses | The Online Metabolic and Molecular Bases of Inherited Disease | OMMBID | McGraw Hill Medical","author":"Neufeld","key":"10.1016\/j.ymgmr.2023.100956_bb0005"},{"key":"10.1016\/j.ymgmr.2023.100956_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.2007.00212.x","article-title":"A clinical study of 77 patients with mucopolysaccharidosis type II","volume":"96","author":"Schwartz","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vhri.2015.08.002","article-title":"Medical costs related to enzyme replacement therapy for Mucopolysaccharidosis types I, II, and VI in Brazil: a multicenter study","volume":"8","author":"Bitencourt","year":"2015","journal-title":"Value Heal. Reg. Issues"},{"key":"10.1016\/j.ymgmr.2023.100956_bb0025","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0030","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for Neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0035","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic Mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094854","article-title":"Current and future treatment of Mucopolysaccharidosis (MPS) type II: is brain-targeted stem cell gene therapy the solution for this devastating disorder?","volume":"23","author":"Horgan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0045","first-page":"62","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7 years follow-up","volume":"12","author":"Barth","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.24246","article-title":"Early treatment is associated with improved cognition in Hurler syndrome","volume":"76","author":"Poe","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0055","series-title":"JIMD Reports","first-page":"81","article-title":"Effectiveness of early hematopoietic stem cell transplantation in preventing neurocognitive decline in mucopolysaccharidosis type ii: A case series","volume":"vol. 41","author":"Selvanathan","year":"2018"},{"key":"10.1016\/j.ymgmr.2023.100956_bb0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/hum.2014.158","article-title":"Hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of Mucopolysaccharidosis type II","volume":"26","author":"Wakabayashi","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0065","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/hum.2022.141","article-title":"Phenotypic correction of murine mucopolysaccharidosis type II by engraftment of ex vivo lentiviral vector transduced hematopoietic stem and progenitor cells","volume":"33","author":"Smith","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0070","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Fe Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0075","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2020.06.007","article-title":"Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy","volume":"130","author":"Miwa","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0080","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/hmg\/ddl038","article-title":"Correction of hunter syndrome in the MPSII mouse model by AAV2\/8-mediated gene delivery","volume":"15","author":"Cardone","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0085","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system-directed, AAV9-mediated iduronate sulfatase gene transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.omtm.2018.07.005","article-title":"Targeting root cause by systemic scAAV9-hIDS gene delivery: functional correction and reversal of severe MPS II in mice","volume":"10","author":"Fu","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0105","doi-asserted-by":"crossref","first-page":"14032","DOI":"10.1038\/mtm.2014.32","article-title":"Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model","volume":"1","author":"Huda","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0110","article-title":"Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice","volume":"2\u20135","author":"Glascock","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0115","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0120","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System\u2013Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nbd.2011.02.015","article-title":"Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I","volume":"43","author":"Wolf","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0130","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/S1525-0016(16)35623-4","article-title":"High level expression of human Iduronidase throughout the brain in a murine model of Mucopolysaccharidosis type I after NonInvasive AAV-mediated gene delivery to the CNS","volume":"22","author":"Belur","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0135","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1093\/hmg\/ddv168","article-title":"Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan","volume":"24","author":"Weismann","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0140","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neulet.2014.05.044","article-title":"Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection","volume":"576","author":"McLean","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnana.2014.00042","article-title":"Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse","volume":"8","author":"Schuster","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0155","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1096\/fj.14-269092","article-title":"Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates","volume":"29","author":"Mattar","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0160","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1101\/lm.334306","article-title":"Spatial and nonspatial escape strategies in the Barnes maze","volume":"13","author":"Harrison","year":"2006","journal-title":"Learn. Mem."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0165","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/nn.4649","article-title":"Synapse-specific astrocyte gating of amygdala-related behavior","volume":"20","author":"Martin-Fernandez","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0170","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0892-0362(00)00084-2","article-title":"Effects of prenatal cocaine on Morris and Barnes maze tests of spatial learning and memory in the offspring of C57BL\/6J mice","volume":"22","author":"Inman-Wood","year":"2000","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0175","series-title":"JIMD Reports","first-page":"61","article-title":"Detection by urinary gag testing of mucopolysaccharidosis type ii in an at-risk spanish population","volume":"vol. 10","author":"L\u00f3pez-Mar\u00edn","year":"2013"},{"key":"10.1016\/j.ymgmr.2023.100956_bb0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0165-0270(98)00169-1","article-title":"Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer\u2019s disease","volume":"87","author":"Pompl","year":"1999","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.ymgmr.2023.100956_bb0185","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1037\/0735-7044.106.2.274","article-title":"Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning","volume":"106","author":"Phillips","year":"1992","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.27","article-title":"Fetal brain-directed AAV gene therapy results in rapid, robust, and persistent transduction of mouse choroid plexus epithelia","volume":"2","author":"Haddad","year":"2013","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.ymgmr.2023.100956_bb0195","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ymthe.2020.03.018","article-title":"A highly efficacious PS gene editing system corrects metabolic and neurological complications of Mucopolysaccharidosis type I","volume":"28","author":"Ou","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2023.100956_bb0200","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2013.09.008","article-title":"High-dose enzyme replacement therapy in murine hurler syndrome","volume":"111","author":"Ou","year":"2014","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426923000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426923000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:51Z","timestamp":1762001571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426923000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":39,"alternative-id":["S2214426923000022"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2023.100956","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2023.100956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100956"}}